2020

17.04.2020 – Medartis Holding AG

Medartis appoints Lisa Thompson as Member of the Executive Management Board and President North America

Medartis Holding AG / Key word(s): AGMEGM/Personnel
Medartis appoints Lisa Thompson as Member of the Executive Management Board
and President North America

17-Apr-2020 / 17:30 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Medartis Holding AG
Hochbergerstrasse 60E
CH-4057 Basel

PRESS RELEASE

Medartis appoints Lisa Thompson as Member of the Executive Management Board
and President North America

Basel, Switzerland, 17 April 2020 - Medartis Holding AG (SIX: MED), a
leading manufacturer and provider of medical devices for surgical fixation
of bone fractures, has appointed Lisa Thompson as a new member of the
Executive Management Board and President North America effective 27 April
2020. In light of the Covid-19 crisis, Medartis further informs that, from
today's perspective, the achievement of the forecasts for the current year
communicated in early March 2020 is no longer tenable. At the Annual General
Meeting held today in Basel, shareholders approved all proposals put forward
by the Board of Directors by a large majority.

The Board of Directors of Medartis Holding AG has appointed Lisa Thompson as
a new member of the Executive Management Board and President North America,
effective 27 April 2020. Lisa Thompson has more than twenty years of
management and sales experience in osteosynthesis of the upper and lower
extremities. In addition, she has a profound understanding of the largest
and most important market for the industry, the US, for which she will
assume responsibility at Medartis.

After a successful career in the field of extremities, Lisa Thompson worked
as an independent management consultant and interim manager in the medical
technology industry from 2012 to 2017, with mandates including Vice
President Marketing at BioMedical Enterprises and Chief of Staff first at
Medshape and then at Zimmer Biomet, Bone Healing Technologies. She then took
over the latter division as Vice President & General Manager (2017-2019),
successfully restructuring it and leading it to double digit sales growth.
From 2005 to 2011, Lisa Thompson held various management positions at
Stryker Orthopaedics, including Vice President Global Marketing in Trauma &
Extremities and Senior Director Marketing in US Extremities, where she
achieved very strong and sustainable growth in the newly established
extremities business (upper extremity and foot & ankle) within five years.
From 1989 to 2005, she was Global General Manager Bone Growth Technologies
at EBI Medical Systems and held various management positions in the areas of
marketing and products. She started her career as Sales Executive in the
medical sector. Lisa Thompson is a US citizen, holds a bachelor's degree in
fine arts from Fairleigh Dickinson University, Rutherford NJ, and has
completed various management training courses, including at Harvard Business
School, Boston.

Christoph Brönnimann, Chief Executive Officer of Medartis: «The US is our
top priority and Lisa Thompson, a market expert as well as an industry and
extremities specialist, will be strengthening our sales organization and our
Executive Management Board. Lisa is an accomplished, high integrity business
leader with a strong track record of driving sales growth. We are convinced
that she will lead our US subsidiary into a successful future.»

Business outlook
In view of the global spread of Covid-19, the safety of Medartis' employees,
clients and business partners is our top priority. At the same time,
Medartis has taken the necessary measures to ensure business continuity and
provide continued supply of implants and instruments to surgeons and
hospitals around the world.

In the context of the official measures to contain Covid-19, which have been
tightened since mid-March 2020, hospitals are continuing to perform
necessary trauma surgeries, while elective, non-time-critical operations are
being postponed in many places. Medartis generates the majority of its sales
in the trauma field, however, due to the restrictions on freedom of movement
associated with the official measures, a decline in such operations can
currently be observed.

In the first quarter of 2020, this situation was not yet noticeably
reflected in Medartis' sales, which were slightly above the previous year's
level. However, a significant decline in sales is expected for the second
quarter. Accordingly, Medartis has initiated measures to protect
profitability, particularly on the cost side, including short-time work for
employees at the headquarters in Basel and in some subsidiaries. The members
of the Board of Directors and the Executive Management Board have announced
that they will contribute to the measures to preserve liquidity in the form
of decreased salaries and bonuses.

As a result of the uncertainty regarding the duration of the Covid-19
crisis, Medartis is currently unable to estimate the impact on its business
for the full year 2020 and does not consider the guidance for 2020
communicated on 3 March 2020 (sales growth of 10% in local currencies,
adjusted EBITDA margin of 15%) to be tenable. Medartis considers itself well
positioned for a future upturn in business activities thanks to its robust
liquidity and ongoing adjustments to its cost base and, from today's
perspective, confirms its medium-term goals (annual sales growth of over 15%
in local currencies, gradual increase in the adjusted EBITDA margin).

Annual General Meeting 2020
At today's Annual General Meeting, which due to the Covid-19 situation took
place without audience, the shareholders of Medartis approved all proposals
put forward by the Board of Directors by a large majority. Dr. h.c. Thomas
Straumann was re-elected as Chairman of the Board of Directors for the next
one-year term of office. He and all other previous members, Dominik
Ellenrieder, Dr. Jürg Greuter, Dr. med. Daniel Herren, Roland Hess, Willi
Miesch and Damien Tappy, were confirmed for a further term of office. In
addition, Marco Gadola was elected as a new, independent member of the Board
of Directors for the next term of office.

More detailed information as well as the voting results for the individual
agenda items can be found on the Medartis website.

Contact
Patrick Christ
Head Corporate Services
Medartis Holding AG
Phone: +41 61 633 34 70
patrick.christ@medartis.com

About Medartis
Founded in 1997 and headquartered in Basel, Switzerland, Medartis is one of
the world's leading manufacturers and providers of medical devices for
surgical fixation of bone fractures for upper and lower extremities as well
as for the craniomaxillofacial region. Medartis employs over 620 individuals
across its 13 locations, with products offered in over 50 countries
globally. Medartis is committed to providing surgeons and operating theatre
personnel with the most innovative titanium implants and instruments as well
as best in class service. For more information, please visit
www.medartis.com.

Disclaimer
This communication does not constitute an offer or invitation to subscribe
for or purchase any securities of Medartis Holding AG. This publication may
contain certain forward-looking statements and assessments or intentions
concerning the company and its business. Such statements involve certain
risks, uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of the company to be
materially different from those expressed or implied by such statements.
Readers should therefore not place reliance on these statements,
particularly not in connection with any contract or investment decision. The
company disclaims any obligation to update these forward-looking statements,
assessments or intentions. Further, neither the company nor any of its
directors, officers, employees, agents, counsel or advisers nor any other
person makes any representation or warranty, express or implied, as to, and
accordingly no reliance should be placed on, the accuracy or completeness of
the information contained herein or of the views given or implied.


---------------------------------------------------------------------------

End of ad hoc announcement

---------------------------------------------------------------------------

close